US Scrutiny of Germany’s Pharmaceutical Pricing Signals New Phase in Transatlantic Trade Tensions
The United States has initiated an investigation into Germany’s pharmaceutical pricing system, accusing it of artificially suppressing drug prices and shifting the financial burden of pharmaceutical innovation disproportionately onto American patients. This development marks an escalation in US-Europe trade disputes, extending beyond traditional sectors into healthcare and pharmaceutical policy.